Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK021 in Advanced Solid Tumors and Tenosynovial Giant Cell Tumor
NCT04192344Phase 1Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Jan 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of pimicotinib in solid tumor and tenosynovial giant cell tumor (TGCT), sponsored by Abbisko Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities at 4 weeks and Incidence and Severity of Adverse Events. Started Jan 2020; status: recruiting.
02
Drugs
pimicotinib
03
Conditions
solid tumortenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT04192344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192344.